INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Aug 06, 2021 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 160,000 | -- | -- |
Jun 25, 2021 |
Director
Trans History: 466
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 2,084 | -- | -- |
Jun 24, 2021 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Bona fide gift | 211,585 | -- | -- |
May 19, 2021 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Bona fide gift | 41,178 | -- | -- |
May 14, 2021 |
EVP Research and Development
Trans History: 660
|
EVP Research and Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 12,500 | -- | -- |
Apr 15, 2021 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Bona fide gift | 14,000 | -- | -- |
Apr 15, 2021 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Bona fide gift | 5,383 | -- | -- |
Feb 23, 2021 |
Director
Trans History: 742
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,921 | -- | -- |
Feb 23, 2021 |
Director
Trans History: 742
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 248,079 | -- | -- |
Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.